Coronary Artery Disease
Conditions
Brief summary
This trial adopts a prospective, multicenter, randomized controlled, and non-inferiority comparison trial design, and plans to recruit 200 eligible subjects who will be randomly assigned to the experimental group or the control group in a 1:1 ratio. All randomly enrolled subjects will be followed up until 30 days after the surgery.
Detailed description
This trial uses a prospective, multicenter, randomized controlled, non-inferiority comparison design. It is expected that the test group will be non-inferior to the control group in the main effectiveness evaluation index (device success rate). This trial plans to enroll 200 subjects who meet the requirements, and they will be randomly assigned to the test group or the control group in a 1:1 ratio. All randomly enrolled subjects will be followed up for 30 days after percutaneous coronary intervention (PCI) treatment to compare the test group and the control group in the main effectiveness evaluation index (device success rate), secondary effectiveness evaluation indices (immediate lumen gain \[QCA analysis\], surgical success rate, in-hospital major adverse cardiac event \[MACE\] incidence rate, target lesion failure \[TLF\] incidence rate within 30 days after surgery, patient-related composite endpoints \[PoCE\] incidence rate during and within 30 days after surgery, device operation and performance evaluation), and safety evaluation indices (device-related complication incidence rate, adverse event/serious adverse event incidence rate, device defect incidence rate), in order to evaluate the effectiveness and safety of the coronary scoring balloon dilation catheter of the test medical device.
Interventions
DEVICECoronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）
One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
DEVICEScoreFlex NC Coronary Dilatation Catheter
One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
Sponsors
JW Medical Systems Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Voluntary participation in this trial and signed the informed consent form; * 2\. Age: ≥18 and ≤80 years old, regardless of gender; * 3\. The existence of coronary artery stenosis lesions accompanied by evidence of ischemia in the heart (such as symptomatic coronary heart disease, stable/unstable angina pectoris or asymptomatic myocardial ischemia), suitable for percutaneous interventional therapy.
Exclusion criteria
* 1\. Acute myocardial infarction (AMI) within 7 days before surgery; * 2\. Serum creatinine level \>2.0 mg/dL (177 umol/L) within 7 days before surgery; * 3\. Active peptic ulcer or active gastrointestinal bleeding within 1 month before surgery; * 4\. Stroke or transient ischemic attack (TIA) within 3 months before surgery; * 5\. Known left ventricular ejection fraction (LVEF) \<30% (if LVEF is unknown, it can be measured during this surgery); * 6\. Known allergies to aspirin or heparin or the existence of contraindications that prevent the subjects from receiving sufficient preoperative medications; * 7\. Known subjects allergic to ingredients in the test product or contrast agent; * 8\. Known subjects who are pregnant or breastfeeding; * 9\. Planned to use coronary atherectomy, laser ablation, other scoring / spiked / cutting balloons (non-study devices) or shock wave balloons to treat the target lesion at the same time; * 10\. Subjects participating in other drug or device clinical studies; * 11\. Other situations that are not suitable for participation in this study as assessed by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of successful device usage | 1hour | The investigational device was successfully delivered to the intended target lesion, dilated, deflated, and retrieved smoothly; After balloon angioplasty with the investigational device, the residual stenosis of the target lesion diameter was \<50%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of success of the surgery | 3 days | The success of the surgery is defined as on the basis of successful use of the instrument, the residual stenosis of the target lesion diameter after PCI is ≤ 30% and TIMI blood flow is grade 3, and no MACE occurs in the hospital. |
| Incidence of in-hospital MACE | 30 days | MACE includes cardiac death, target vessel myocardial infarction, and target lesion re-vascularization |
| Incidence of PoCE within 30 days after surgery | 30 days | PoCE includes all-cause mortality, all MIs, and any re-vascularization |
| The lumen is obtained immediately | 1hour | The lumen is obtained immediately (QCA analysis) |
Contacts
Primary ContactYang Wang, PM
Outcome results
None listed